Holen Sie sich die Stockscreener-App
2.28
1.30%
-0.03
Schlusskurs vom Vortag:
$2.31
Offen:
$2.305
24-Stunden-Volumen:
6,504
Relative Volume:
0.11
Marktkapitalisierung:
$92.32M
Einnahmen:
$1.88M
Nettoeinkommen (Verlust:
$-15.57M
KGV:
-5.70
EPS:
-0.4
Netto-Cashflow:
$-50.09M
1W Leistung:
+0.44%
1M Leistung:
-18.28%
6M Leistung:
+38.18%
1J Leistung:
-2.56%
1-Tages-Spanne:
$2.28
$2.3599
1-Wochen-Bereich:
$2.21
$2.40
52-Wochen-Spanne:
$0.98
$3.44
Beyondspring Inc Stock (BYSI) Company Profile
Firmenname
Beyondspring Inc
Sektor
Branche
Telefon
646-528-4184
Adresse
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Vergleichen Sie BYSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
2.29 | 91.52M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.41 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.84 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.75 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.00 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
251.88 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-12-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | Eingeleitet | BofA Securities | Buy |
| 2020-12-29 | Eingeleitet | Evercore ISI | Outperform |
| 2020-02-07 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | Nomura | Buy |
| 2019-12-03 | Eingeleitet | William Blair | Outperform |
| 2019-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-30 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-10-25 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Beyondspring Inc Aktie (BYSI) Neueste Nachrichten
BeyondSpring Inc. Reports Promising Results of Plinabulin Combination Therapy in Patients Refractory to Immune Checkpoint Inhibitors - Nasdaq
BeyondSpring reports positive results for Plinabulin combination in ICI-resistant tumors - Investing.com
BeyondSpring Publishes Human Clinical Study in Med (Cell - GlobeNewswire
BeyondSpring (NASDAQ:BYSI) Shares Down 4.1%What's Next? - MarketBeat
Cancer index outperforms broader markets with 13% Q2 rebound - BioWorld MedTech
BeyondSpring (NASDAQ:BYSI) Shares Up 30%Should You Buy? - MarketBeat
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - The Globe and Mail
BeyondSpring reports promising phase 2 NSCLC study results By Investing.com - Investing.com South Africa
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study - GuruFocus
BeyondSpring Inc. Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - marketscreener.com
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com Australia
BeyondSpring (BYSI) Presents Promising Phase 2 Data in Lung Canc - GuruFocus
BeyondSpring (BYSI) Presents Promising Phase 2 Data in Lung Cancer Study | BYSI Stock News - GuruFocus
BeyondSpring Inc. Reports Promising Interim Phase 2 Data for Plinabulin in Metastatic NSCLC Showing 6.8 Months Median PFS and 78% Overall Survival Rate - Nasdaq
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 - GlobeNewswire
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - TradingView
New Clinical Data: BeyondSpring's Triple Therapy Doubles Survival in Drug-Resistant Lung Cancer Patients - Stock Titan
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting | BYSI Stock News - GuruFocus
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting - GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
BeyondSpring and Merck's Triple Therapy Shows Promise in Advanced Lung Cancer After Immunotherapy Failure - Stock Titan
Neutropenia Drugs Market Revenue to Surpass USD 24.2 Billion by 2033 with 4.7% CAGR - openPR.com
Should You Buy, Hold or Sell OKTA Stock Before Q1 Earnings Release? - The Globe and Mail
BeyondSpring Reports Q1 2025 Financials and Clinical Progress - TipRanks
BeyondSpring (NASDAQ:BYSI) Posts Earnings Results - MarketBeat
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth? - Yahoo Finance
Can Saudi AI Deals Boost AMD Over NVIDIA, and Is It a Buy? - The Globe and Mail
BeyondSpring Inc. (BYSI) Reports Q1 Loss of $0.08 - StreetInsider
BeyondSpring Reports First?Quarter 2025 Financial Results and Provides Corporate Update | BYSI Stock News - GuruFocus
BeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress - Nasdaq
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring (NASDAQ:BYSI) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
BeyondSpring stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.34 amid market challenges - Investing.com India
BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat
BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com
BeyondSpring Inc. (BYSI) reports earnings - Quartz
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times
Finanzdaten der Beyondspring Inc-Aktie (BYSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
1.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):